Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-1.
暂无分享,去创建一个
M. Raffeld | E. Leonard | T. Yoshimura | S. Tanaka | Edward J. Leonard | Teizo Yoshimura | Shuji Tanaka
[1] E. Leonard,et al. Leukocyte specificity and binding of human neutrophil attractant/activation protein-1. , 1990, Journal of immunology.
[2] J. Westwick,et al. Potent and specific inhibition of IL-8-, IL-1α- and IL-1β-inducedin vitro human lymphocyte migration by calcium channel antagonists , 1989 .
[3] B. Dewald,et al. The neutrophil-activating peptide NAF/NAP-1 induces histamine and leukotriene release by interleukin 3-primed basophils , 1989, The Journal of experimental medicine.
[4] K. Yancey,et al. Inflammatory properties of human C5a and C5a des Arg/ in mast cell-depleted human skin. , 1989, Journal of Investigative Dermatology.
[5] M. Yamada,et al. Production and characterization of recombinant human neutrophil chemotactic factor. , 1989, Journal of biochemistry.
[6] M. Kaliner,et al. Neutrophil attractant/activation protein-1 (NAP-1) causes human basophil histamine release. , 1989, Immunology letters.
[7] J. Van Damme,et al. Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin. , 1989, The American journal of pathology.
[8] B. Dewald,et al. In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes. , 1989, The American journal of pathology.
[9] E. Appella,et al. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. , 1989, Science.
[10] R. Strieter,et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. , 1989, Science.
[11] J. Schröder,et al. Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells. , 1989, Journal of immunology.
[12] E. Appella,et al. Three forms of monocyte-derived neutrophil chemotactic factor (MDNCF) distinguished by different lengths of the amino-terminal sequence. , 1989, Molecular immunology.
[13] E. Appella,et al. Synthesis and biological characterization of monocyte‐derived neutrophil chemotactic factor , 1988, FEBS letters.
[14] E. Appella,et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor , 1988, The Journal of experimental medicine.
[15] B. Dewald,et al. A novel neutrophil-activating factor produced by human mononuclear phagocytes , 1988, The Journal of experimental medicine.
[16] J. van Beeumen,et al. A novel, NH2-terminal sequence-characterized human monokine possessing neutrophil chemotactic, skin-reactive, and granulocytosis-promoting activity , 1988, The Journal of experimental medicine.
[17] T. Herlin,et al. Human monocyte and polymorphonuclear leukocyte chemotactic and chemokinetic responses to leukotriene B4 and FMLP. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.
[18] E. Appella,et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[19] J. Schröder,et al. Purification and partial biochemical characterization of a human monocyte-derived, neutrophil-activating peptide that lacks interleukin 1 activity. , 1987, Journal of immunology.
[20] E. Leonard,et al. A series of six ligands for the human formyl peptide receptor: tetrapeptides with high chemotactic potency and efficacy. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[21] K. Matsushima,et al. Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin 1 (IL 1). , 1987, Journal of immunology.
[22] R. Cotran,et al. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. , 1985, The Journal of clinical investigation.
[23] K. Yancey,et al. Studies of human C5a as a mediator of inflammation in normal human skin. , 1985, The Journal of clinical investigation.
[24] H. Perez,et al. Biologically active complement (C5)-derived peptides and their relevance to disease. , 1984, Critical reviews in oncology/hematology.
[25] K. Frank Austen,et al. Local Effects of Synthetic Leukotrienes (LTC4, LTD4, and LTB4) in Human Skin , 1983 .
[26] R. Snyderman,et al. Molecular and cellular mechanisms of leukocyte chemotaxis. , 1981, Science.
[27] T. Williams,et al. Mediation of increased vascular permeability after complement activation. Histamine-independent action of rabbit C5a , 1981, The Journal of experimental medicine.
[28] E. Melby,et al. CRC handbook of laboratory animal science , 1974 .